Literature DB >> 1335979

The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.

P Mårin1, S Holmäng, L Jönsson, L Sjöström, H Kvist, G Holm, G Lindstedt, P Björntorp.   

Abstract

Twenty-three middle-aged abdominally obese men were treated for eight months with testosterone or with placebo. Testosterone treatment was followed by a decrease of visceral fat mass, measured by computerized tomography, without a change in body mass, subcutaneous fat mass or lean body mass. Insulin resistance, measured by the euglycemic/hyperinsulinemic glucose clamp method, improved and blood glucose, diastolic blood pressure and serum cholesterol decreased with testosterone treatment. A small increase in prostate volume was noted, but serum prostate specific antigen concentrations were unchanged and no adverse functional side-effects were found. Insulin sensitivity improved more in men with relatively low testosterone values at the outset. The mechanisms involved in these changes might act either via effects on visceral fat accumulation, followed by metabolic improvements, and/or via direct effects on muscle insulin sensitivity, as suggested by results of other recent studies. It is concluded that testosterone treatment of middle-aged abdominally obese men gives beneficial effects on well-being and the cardiovascular and diabetes risk profile, results similar to those observed after hormonal replacement therapy in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335979

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  86 in total

1.  Metabolic Complications of HIV and AIDS.

Authors:  Alison Strawford; Marc K. Hellerstein
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

Review 2.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Andropause: to treat or not to treat?

Authors:  S Basaria; A Dobs
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

Review 4.  Effects of androgen replacement on metabolism and physical performances in male hypogonadism.

Authors:  M Zitzmann; E Nieschlag
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 5.  Surgical recovery of sperm in non-obstructive azoospermia.

Authors:  Tomomoto Ishikawa
Journal:  Asian J Androl       Date:  2011-11-28       Impact factor: 3.285

Review 6.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

7.  Testosterone replacement attenuates cognitive decline in testosterone-deprived lean rats, but not in obese rats, by mitigating brain oxidative stress.

Authors:  Hiranya Pintana; Wanpitak Pongkan; Wasana Pratchayasakul; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Age (Dordr)       Date:  2015-08-16

8.  The relationships between testosterone, body composition, and insulin resistance: a lesson from a case of extreme hyperandrogenism.

Authors:  Elena Volpi; Steven A Lieberman; Dennis M Ferrer; Charles R Gilkison; Blake B Rasmussen; Manubai Nagamani; Randall J Urban
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

9.  Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study.

Authors:  Zeki Yesilova; Cagatay Oktenli; S Yavuz Sanisoglu; Ugur Musabak; Erdinc Cakir; Metin Ozata; Kemal Dagalp
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

10.  Testosterone and growth hormone improve body composition and muscle performance in older men.

Authors:  Fred R Sattler; Carmen Castaneda-Sceppa; Ellen F Binder; E Todd Schroeder; Ying Wang; Shalender Bhasin; Miwa Kawakubo; Yolanda Stewart; Kevin E Yarasheski; Jagadish Ulloor; Patrick Colletti; Ronenn Roubenoff; Stanley P Azen
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.